文献速递血脂与心血管预防

REDUCE-IT研究中研究者报告与裁定缺血事件的比较

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

REDUCE-IT试验将接受他汀治疗的高甘油三酯患者随机分配至二十碳五烯酸乙酯(IPE)或安慰剂组,比较研究者报告与盲法临床终点委员会(CEC)裁定事件的一致性。研究者报告与裁定终点高度一致,IPE显著降低主要终点和关键次要终点发生率,裁定事件结果相似。

要点

  • 研究者报告与CEC裁定终点高度一致(主要终点Kappa 0.89,关键次要终点0.90)。
  • IPE显著降低研究者报告的主要终点(19.1% vs 24.6%;HR 0.74;P<0.0001)。
  • IPE显著降低研究者报告的关键次要终点(10.5% vs 13.6%;HR 0.75;P<0.0001)。

核心结论

  • IPE在盲法研究者报告和独立盲法CEC裁定中均一致且显著降低心血管事件,包括心肌梗死和冠状动脉血运重建。

研究设计与样本

  • REDUCE-IT随机对照试验,纳入8,179例接受他汀治疗的高甘油三酯患者,比较IPE与安慰剂。
  • 潜在终点由盲法站点研究者收集,并由盲法临床终点委员会(CEC)根据预设章程裁定。

主要发现

  • 研究者报告与裁定终点高度一致:主要终点简单Kappa统计量为0.89,关键次要终点为0.90。
  • 基于研究者报告事件,IPE显著降低主要终点发生率(19.1% vs 24.6%;HR: 0.74 [95% CI: 0.67-0.81];P < 0.0001)。
  • 基于研究者报告事件,IPE显著降低关键次要终点发生率(10.5% vs 13.6%;HR: 0.75 [95% CI: 0.66-0.85];P < 0.0001)。
  • 在裁定事件中,IPE同样降低主要和关键次要终点发生率。

临床怎么用

  • REDUCE-IT中IPE的心血管获益在研究者报告和CEC裁定下一致,支持其稳健性。
  • 结果提出在盲法安慰剂对照试验中是否常规需要裁定心血管终点的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) randomized statin-treated patients with elevated triglycerides to icosapent ethyl (IPE) or placebo. There was a significant reduction in adjudicated events, including the primary endpoint (cardiovascular [CV] death, myocardial infarction [MI], stroke, coronary revascularization, unstable angina requiring hospitalization) and key secondary endpoint (CV death, MI, stroke) with IPE. OBJECTIVES: The purpose of this study was to determine the effects of IPE on investigator-reported events. METHODS: Potential endpoints were collected by blinded site investigators and subsequently adjudicated by a blinded Clinical Endpoint Committee (CEC) according to a prespecified charter. Investigator-reported events were compared with adjudicated events for concordance. RESULTS: There was a high degree of concordance between investigator-reported and adjudicated endpoints. The simple Kappa statistic between CEC-adjudicated vs site-reported events for the primary endpoint was 0.89 and for the key secondary endpoint was 0.90. Based on investigator-reported events in 8,179 randomized patients, IPE significantly reduced the rate of the primary endpoint (19.1% vs 24.6%; HR: 0.74 [95% CI: 0.67-0.81]; P < 0.0001) and the key secondary endpoint (10.5% vs 13.6%; HR: 0.75 [95% CI: 0.66-0.85]; P < 0.0001). Among adjudicated events, IPE similarly reduced the rate of the primary and key secondary endpoints. CONCLUSIONS: IPE led to consistent, significant reductions in CV events, including MI and coronary revascularization, as determined by independent, blinded CEC adjudication as well as by blinded investigator-reported assessment. These results highlight the robust evidence for the substantial CV benefits of IPE seen in REDUCE-IT and further raise the question of whether adjudication of CV outcome trial endpoints is routinely required in blinded, placebo-controlled trials. (Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT [Reduction of Cardiovascular Events With EPA - Intervention Trial]; NCT01492361).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gaba P, Bhatt DL, Giugliano RP, et al. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. J Am Coll Cardiol. 2021. PMID: 34620410. doi:10.1016/j.jacc.2021.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。